Cara Therapeutics CARA

Cara Therapeutics Inc is a clinical-stage specialist biopharmaceutical company engaged in the discovery, development, and commercialisation of pharmaceutical solutions. It focuses on peripheral nervous system pain relief by selectively targeting the body’s peripheral kappa opioid receptors. The main focus of the company’s work is pursuing novel pruritus therapies to transform the way the condition is treated and improve the quality of life for those who suffer from it. Operating globally, the firm has its headquarters in Stamford, Connecticut, and was founded in 2004.

The firm’s main commercial product is KORSUVA, a medication administered by injection that is designed to treat patients suffering with moderate to severe pruritus as a result of chronic kidney disease. The firm has other products in its pipeline undergoing clinical trials, including oral therapies for patients with pruritus. The firm primarily aims to treat patients suffering from pruritis as a result of chronic kidney disease and chronic liver disease.

The company runs regular clinical trials as part of its rigorous research programmes, and patients are encouraged to get in touch if they would like to participate. The firm is listed on the NASDAQ, where it trades under the ticker CARA.

Follow the CARA share price on eToro by adding this stock to your eToro watchlist.